Grants Awarded

Click on any project title for a more detailed description of the project. For more information about any of these awards (e.g., PI contact information or associated publications), please use the corresponding project number to search for information at the NIH Reporter website. Consistent with NIH policy, abstracts are not available for projects receiving their first award within the past year, so descriptions provided below are from the NCI program director.

New awards will be posted as they are issued.

Year Award Type Project # RFA # PI/Project Leader Institution Title Statussort ascending
2021 R33 RFA-CA-20-018 HANSEN, ANDERS SEJR MASSACHUSETTS INSTITUTE OF TECHNOLOGY Super-resolution microscopy for dynamic analysis of focal enhancer amplifications in cancer Active
2020 R21 RFA-CA-19-019 ALEXANDRAKIS, GEORGIOS UNIVERSITY OF TEXAS ARLINGTON Nanotechnology Enabled Selection Of MHC-peptide Ligands To Personalize Cancer Therapy Active
2019 R21 RFA-CA-18-002 MONTAGNA, CRISTINA ALBERT EINSTEIN COLLEGE OF MEDICINE Development of a high-resolution mapping platform for HPV DNA integration in premalignant lesions Active
2022 R21 CA21-003 LIN, QIAO COLUMBIA UNIV NEW YORK MORNINGSIDE A Practical Approach to Tumor-Specific Aptamers for B-Cell Hematologic Malignancies Active
2021 R33 RFA-CA-20-018 LIU, XUEFENG OHIO STATE UNIVERSITY Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer Clinics Active
2020 R33 RFA-CA-19-020 MATRIX BHATNAGAR, PARIJAT SRI INTERNATIONAL T-cell Biofactories For Targeting Extracellular Matrix Active
2019 R33 RFA-CA-18-003 KETTENBACH, ARMINJA NADINE DARTMOUTH COLLEGE Activity based profiling of Phosphoprotein phosphatases in cancer using mass spectrometry-based proteomics Active
2022 R21 CA21-003 YAKOVLEV, VLADISLAV V TEXAS ENGINEERING EXPERIMENT STATION Molecular and cellular imaging of bone biopsies using AI augmented deep UV Raman microscopy Active
2021 R44 PAR-18-303 HUNG, PAUL JU-SUNG COMBINATI, INC. Digital Melt Curve Analysis Platform for Longitudinal Cancer Patient Monitoring Active
2020 R33 RFA-CA-19-020 COOKS, ROBERT GRAHAM PURDUE UNIVERSITY Advanced Development Of Desorption Electrospray Ionization Mass Spectrometry For Intraoperative Molecular Diagnosis Of Brain Cancer Using Pathology Biopsies Active
2019 R33 RFA-CA-18-003 CHEN, SIDI YALE UNIVERSITY Rapidly scalable platforms for direct in vivo screening of functional drivers in lethal cancers Active
2022 R33 CA21-004 CHIU, BRIAN C-H UNIVERSITY OF CHICAGO A highly sensitive linear amplification based DNA methylation profiling technique for clinical cancer research Active
2020 R21 RFA-CA-19-021 GUPTA, GAUTAM UNIVERSITY OF LOUISVILLE Bio Cargos: Capture And Release Gels For Optimized Storage Of Cancer Biospecimens Active
2019 R33 RFA-CA-18-003 TAVANA, HOSSEIN UNIVERSITY OF AKRON A High Throughput Human Tumor Modeling Technology for Cancer Drug Discovery Active
2018 R33 RFA-CA-17-011 SCHRUM, ADAM G UNIVERSITY OF MISSOURI-COLUMBIA Multiplex matrix ELISA for T cell protein-interaction networks in cancer Active
2022 R21 CA21-003 BLAINEY, PAUL CLARK BROAD INSTITUTE, INC. Stitch-seq for genome-wide pooled genomic screening with RNA-seq readout Active
2020 R44 PAR-18-303 GURARD-LEVIN, ZACHARY SAMDI TECH, INC. Development Of The First Label-free And High-throughput, Cell-based Assay That Reports On Specific Enzyme Activities Active
2019 R33 RFA-CA-18-003 SCHNECK, JONATHAN P JOHNS HOPKINS UNIVERSITY A high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cells Active
2018 R33 RFA-CA-17-011 TEWARI, MUNEESH (contact); WALTER, NILS G UNIVERSITY OF MICHIGAN AT ANN ARBOR Optimization and Validation of Single-Molecule Kinetic Fingerprinting Technology for Rapid, Ultra-Specific Detection of Cancer Mutations Active
2022 R21 CA21-003 SALIPANTE, STEPHEN J UNIVERSITY OF WASHINGTON Efficient, cost-effective, and ultrasensitive sequencing of somatic mutations Active
2020 R21 RFA-CA-19-019 HATTORI, TAKAMITSU NEW YORK UNIVERSITY SCHOOL OF MEDICINE Rational Generation Of High-performance Recombinant Antibodies To Post-translational Modifications Active